TTK Healthcare Limited (TTKHLTCARE) Fair Value & Analysis
Healthcare · IN · Market cap ₹12.9B
Fair value as of: Aug 13, 2026
From 17 valuation models · updated 4 days ago
Share price +16.1% over the past month.
Below-average quality, and screening another 47% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (₹612.31). The favourable scenario is already priced in.
- Solid but not exceptional quality (47/100) and above fair value, neither a clear bargain nor a standout compounder.
- The models converge in a tight band (₹592.64 to ₹612.31), unusually little disagreement for a valuation.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range ₹547.28 – ₹1,829 · fair‑value band ₹592.64 – ₹612.31 · the ₹1,138 price screens above the ₹598.21 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
TTK Healthcare Limited (TTKHLTCARE) currently trades at ₹1,138, while our model-based Fair Value estimate is ₹598.21, implying the stock looks roughly 47.5% overvalued today. The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, TTK Healthcare Limited generated revenue of ₹8.6B at a net margin of 7.7%. Revenue grew 14.5% year over year. It earns a return on equity of 6.0%. Net debt stands at ₹25.0M. Fundamentals as of Aug 13, 2026
Our scenario range runs from ₹592.64 (bear case) to ₹612.31 (bull case); at ₹1,138, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 18% below its 52-week high and 55% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -20% fair-value upside, at -47%, TTKHLTCARE screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 17 models by family
Widest divergence: Growth Earnings (₹939.08) versus Economic Profit (₹83.96). Highest evidence: Residual Income (76).
Notify me when TTKHLTCARE reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 46 · Market factors (momentum, volatility) 62
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
TTK Healthcare Limited engages in the animal welfare, consumer product, medical device, protective device, food, and other businesses in India. It operates through Animal Welfare, Consumer Products, Medical Devices, Protective Devices, Foods, and Others segments.
Full company description
TTK Healthcare Limited engages in the animal welfare, consumer product, medical device, protective device, food, and other businesses in India. It operates through Animal Welfare, Consumer Products, Medical Devices, Protective Devices, Foods, and Others segments. The Animal Welfare segment offers various feed supplements, liver correctives, fertility inducers, antibiotics, antiparasiticides, antispasmodics, cervical dilators, cocktail enzymes, etc. to veterinarians, dairy, poultry and aqua farmers, and pet parents. The Consumer Products segment is involved in the marketing and distribution of baby care products under the Woodward's Gripe water name; personal care products and cosmetics under the EVA name; home care products, such as scrubbers under the Good Home name; and air fresheners. The Medical Devices segment manufactures and markets artificial heart valves under the TTK Chitra name, as well as orthopedic implants and instruments for knee and hip replacements. The Protective Devices segment manufactures and markets sexual wellness products, including male contraceptives under the Skore brand name, and other allied products. The Foods segment engages in the manufacturing and marketing of food products, including papads under the Fryums name; and cereal, potato, rice, pulses, and corn-based products. The Others segment prints and publishes maps, atlases, guidebooks, and educational publications under the TTK brand name. The company was founded in 1928 and is headquartered in Chennai, India. TTK Healthcare Limited operates as a subsidiary of TT Krishnamachari & Co., Ltd.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
TTK Healthcare Limited reported revenue of ₹8.6B in FY2026 versus ₹6.0B in FY2022, a compound +9.4%/yr. Reported net income was ₹657M in FY2026, compounding +12.1%/yr from FY2022.
of which total revenue +5.5 pp · buybacks/dilution +0.0 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
TTKHLTCARE screens 47% overvalued. Compare with Eli Lilly and Company →
Peer Group
Drug Manufacturers - General · 77 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - General median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,220 | $389.47 | -68% |
| Johnson & Johnson, JNJ | $260.86 | $169.04 | -35% |
| AbbVie Inc ABBV | $248.76 | $67.72 | -73% |
| Roche Holding 1RO | €392.80 | €240.14 | -39% |
| Merck & Co MRK | €115.42 | €118.21 | +2% |
| Novartis AG NVSN | 2,742 MXN | 1,964 MXN | -28% |
| AstraZeneca PLC AZN | $158.50 | $127.32 | -20% |
| Novo Nordisk A/S NOVOB | kr 299.50 | kr 409.46 | +37% |
| Sanofi SNYN | 770.00 MXN | 1,041 MXN | +35% |
| GSK plc GSKN | 917.00 MXN | 879.08 MXN | -4% |
Compare TTK Healthcare Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is TTK Healthcare Limited (TTKHLTCARE) overvalued or undervalued?
What is the fair value of TTKHLTCARE?
What is the quality score of TTKHLTCARE?
What is the revenue of TTK Healthcare Limited (TTKHLTCARE)?
What is the net profit margin of TTKHLTCARE?
Does TTK Healthcare Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track TTK Healthcare Limited and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.